已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

多西紫杉醇 雄激素剥夺疗法 医学 前列腺癌 肿瘤科 内科学 危险系数 临床终点 随机对照试验 荟萃分析 置信区间 雄激素受体 癌症
作者
Soumyajit Roy,Rashid K. Sayyid,Fred Saad,Yilun Sun,Katherine Lajkosz,Michael Ong,Zachary Klaassen,Shawn Malone,Daniel E. Spratt,Christopher J.D. Wallis,Scott C. Morgan
出处
期刊:European Urology Oncology [Elsevier]
卷期号:5 (5): 494-502 被引量:28
标识
DOI:10.1016/j.euo.2022.06.003
摘要

Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis-targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit.To compare the efficacy of ADT plus ARAT with the triplet of ADT, ARAT, and docetaxel through a network meta-analysis (NMA) of RCTs in mHSPC.Bibliographic databases and conference proceedings were searched in March 2022 for RCTs that evaluated the addition of docetaxel, ARAT, or both to ADT in mHSPC. The primary endpoint was OS. Standard random-effect NMA and Bayesian analyses were performed to compare ADT plus ARAT with triplet therapy.Eleven RCTs (n = 11 546) were eligible. Compared with ADT plus ARAT, the triplet had a nonsignificant OS benefit (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.68-1.16), while ADT plus docetaxel (HR 1.16 [0.94-1.43]) and ADT alone (HR 1.46 [1.30-1.64]) had an increased risk of death. By P-score ordering, the triplet was the most effective treatment strategy (P score = 0.936) followed by ADT plus ARAT (P score = 0.704). The triplet had a 77% likelihood of being the best treatment strategy compared with a 23% likelihood for ADT plus ARAT.The triplet of ADT, ARAT, and docetaxel was the highest ranked treatment strategy, but it did not confer a statistically significant OS benefit over ADT plus ARAT. This NMA provides the highest-level comparative evidence for these treatment approaches in the initial management of mHSPC.We synthesized the available evidence from clinical trials conducted in newly diagnosed metastatic prostate cancer to compare the survival of patients receiving triplet therapy (androgen receptor axis-targeted therapy [ARAT], androgen deprivation therapy [ADT], and docetaxel) with those receiving only ARAT and ADT. We conclude that the triplet is a somewhat more effective treatment approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luster完成签到 ,获得积分10
刚刚
1秒前
丘比特应助酷酷河马采纳,获得10
3秒前
4秒前
5秒前
7秒前
lei完成签到,获得积分10
8秒前
wang完成签到,获得积分10
9秒前
9秒前
semigreen完成签到 ,获得积分10
9秒前
yaqin@9909发布了新的文献求助10
10秒前
爱学习的瑞瑞子完成签到 ,获得积分10
11秒前
英姑应助huihui采纳,获得10
11秒前
liujunjie完成签到,获得积分20
11秒前
ding应助Zhang采纳,获得10
12秒前
科研通AI2S应助may采纳,获得10
13秒前
星空发布了新的文献求助20
14秒前
搞科研的小李同学完成签到 ,获得积分10
15秒前
16秒前
大个应助迷路的钻石采纳,获得10
17秒前
赖皮蛇完成签到,获得积分10
17秒前
wanci应助小魏同学采纳,获得10
18秒前
pluto应助青铜伤疤采纳,获得10
18秒前
19秒前
晚风完成签到,获得积分10
19秒前
传奇3应助赤道采纳,获得10
20秒前
酷酷河马发布了新的文献求助10
21秒前
思源应助毛竹采纳,获得10
24秒前
萧水白应助晚风采纳,获得10
24秒前
所所应助IIIIIIIIII采纳,获得10
24秒前
24秒前
27秒前
调研昵称发布了新的文献求助50
27秒前
酷酷河马完成签到,获得积分10
28秒前
uziMOF发布了新的文献求助10
28秒前
29秒前
30秒前
寻度完成签到,获得积分10
30秒前
双黄应助mulidexin2021采纳,获得10
30秒前
尼尼发布了新的文献求助10
31秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248529
求助须知:如何正确求助?哪些是违规求助? 2891960
关于积分的说明 8269265
捐赠科研通 2559983
什么是DOI,文献DOI怎么找? 1388824
科研通“疑难数据库(出版商)”最低求助积分说明 650913
邀请新用户注册赠送积分活动 627798